BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 10788589)

  • 1. MDM2 oncogene as a novel target for human cancer therapy.
    Zhang ; Wang H
    Curr Pharm Des; 2000 Mar; 6(4):393-416. PubMed ID: 10788589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MDM2 oncogene as a target for cancer therapy: An antisense approach.
    Wang H; Zeng X; Oliver P; Le LP; Chen J; Chen L; Zhou W; Agrawal S; Zhang R
    Int J Oncol; 1999 Oct; 15(4):653-60. PubMed ID: 10493945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The mdm2 proto-oncogene.
    Haines DS
    Leuk Lymphoma; 1997 Jul; 26(3-4):227-38. PubMed ID: 9322885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-tumor efficacy of a novel antisense anti-MDM2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms.
    Wang H; Nan L; Yu D; Lindsey JR; Agrawal S; Zhang R
    Mol Med; 2002 Apr; 8(4):185-99. PubMed ID: 12149568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms.
    Wang H; Nan L; Yu D; Agrawal S; Zhang R
    Clin Cancer Res; 2001 Nov; 7(11):3613-24. PubMed ID: 11705884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms.
    Wang H; Yu D; Agrawal S; Zhang R
    Prostate; 2003 Feb; 54(3):194-205. PubMed ID: 12518324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiosensitization by antisense anti-MDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer models.
    Zhang Z; Wang H; Prasad G; Li M; Yu D; Bonner JA; Agrawal S; Zhang R
    Clin Cancer Res; 2004 Feb; 10(4):1263-73. PubMed ID: 14977824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemosensitization by antisense oligonucleotides targeting MDM2.
    Bianco R; Ciardiello F; Tortora G
    Curr Cancer Drug Targets; 2005 Feb; 5(1):51-6. PubMed ID: 15720189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Mdm2, p53 and the cell cycle: when well enough is best left alone].
    Maréchal V
    Pathol Biol (Paris); 1997 Dec; 45(10):824-32. PubMed ID: 9769946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small molecule antagonists of the MDM2 oncoprotein as anticancer agents.
    Buolamwini JK; Addo J; Kamath S; Patil S; Mason D; Ores M
    Curr Cancer Drug Targets; 2005 Feb; 5(1):57-68. PubMed ID: 15720190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemosensitization and radiosensitization of human cancer by antisense anti-MDM2 oligonucleotides: in vitro and in vivo activities and mechanisms.
    Wang H; Oliver P; Zhang Z; Agrawal S; Zhang R
    Ann N Y Acad Sci; 2003 Dec; 1002():217-35. PubMed ID: 14751837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage.
    Chen L; Agrawal S; Zhou W; Zhang R; Chen J
    Proc Natl Acad Sci U S A; 1998 Jan; 95(1):195-200. PubMed ID: 9419352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The p53-MDM2 interaction in a cancer-prone family, and the identification of a novel therapeutic target.
    Picksley SM; Spicer JF; Barnes DM; Lane DP
    Acta Oncol; 1996; 35(4):429-34. PubMed ID: 8695156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P53 and MDM2 co-expression in tobacco and betel chewing-associated oral squamous cell carcinomas.
    Shwe M; Chiguchi G; Yamada S; Nakajima T; Maung KK; Takagi M; Amagasa T; Tsuchida N
    J Med Dent Sci; 2001 Dec; 48(4):113-9. PubMed ID: 12160248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibiting the p53-MDM2 interaction: an important target for cancer therapy.
    Chène P
    Nat Rev Cancer; 2003 Feb; 3(2):102-9. PubMed ID: 12563309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53-independent activities of MDM2 and their relevance to cancer therapy.
    Zhang Z; Zhang R
    Curr Cancer Drug Targets; 2005 Feb; 5(1):9-20. PubMed ID: 15720185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy.
    Zhang Z; Li M; Wang H; Agrawal S; Zhang R
    Proc Natl Acad Sci U S A; 2003 Sep; 100(20):11636-41. PubMed ID: 13130078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adenovirus-mediated E2F-1 gene transfer inhibits MDM2 expression and efficiently induces apoptosis in MDM2-overexpressing tumor cells.
    Yang HL; Dong YB; Elliott MJ; Liu TJ; Atienza C; Stilwell A; McMasters KM
    Clin Cancer Res; 1999 Aug; 5(8):2242-50. PubMed ID: 10473112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functions of the MDM2 oncoprotein.
    Freedman DA; Wu L; Levine AJ
    Cell Mol Life Sci; 1999 Jan; 55(1):96-107. PubMed ID: 10065155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel antisense anti-MDM2 mixed-backbone oligonucleotides: proof of principle, in vitro and in vivo activities, and mechanisms.
    Zhang R; Wang H; Agrawal S
    Curr Cancer Drug Targets; 2005 Feb; 5(1):43-9. PubMed ID: 15720188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.